IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
0.9999
-0.0001 (-0.01%)
At close: Oct 7, 2025, 4:00 PM EDT
1.000
+0.000 (0.01%)
After-hours: Oct 7, 2025, 7:59 PM EDT
IceCure Medical Revenue
IceCure Medical had revenue of $525.00K in the quarter ending June 30, 2025, a decrease of -48.07%. This brings the company's revenue in the last twelve months to $2.79M, down -16.46% year-over-year. In the year 2024, IceCure Medical had annual revenue of $3.29M with 1.92% growth.
Revenue (ttm)
$2.79M
Revenue Growth
-16.46%
P/S Ratio
20.10
Revenue / Employee
$42,227
Employees
66
Market Cap
68.94M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.29M | 62.00K | 1.92% |
| Dec 31, 2023 | 3.23M | 144.00K | 4.67% |
| Dec 31, 2022 | 3.09M | -1.05M | -25.45% |
| Dec 31, 2021 | 4.14M | 270.00K | 6.98% |
| Dec 31, 2020 | 3.87M | 2.21M | 132.76% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ICCM News
- 1 day ago - IceCure Medical Ltd - Special Call - Seeking Alpha
- 4 days ago - IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care - PRNewsWire
- 4 days ago - IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above - PRNewsWire
- 7 days ago - IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented - PRNewsWire
- 15 days ago - IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented - PRNewsWire
- 19 days ago - IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes - PRNewsWire
- 22 days ago - IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications - PRNewsWire
- 4 weeks ago - Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate - PRNewsWire